Background: Digoxin, a cardiac glycoside used for the treatment of heart failure, was reported to inhibit the retinoid-related orphan receptor gamma t
I
nflammatory bowel diseases (IBDs), such as Crohn's disease and ulcerative colitis, are characterized by chronic gastrointestinal inflammation that is caused by various genetic and environmental factors, and it is well known that dysregulated CD4 + T-cell responses play a critical role in the development of these diseases. [1] [2] [3] During the last 2 decades, the helper type 1 (Th1)/Th2 paradigm has been used to explain the pathogenic mechanisms involved in several inflammatory/immune disorders including IBDs. 4 It has been assumed that Crohn's disease is mainly mediated by Th1 cells, whereas ulcerative colitis is associated predominantly with Th2 responses. 5, 6 However, since the discovery of Th17 cells, the understanding of the immunopathogenesis of IBDs changed dramatically. [7] [8] [9] Indeed, Th17-derived cytokines such as interleukin (IL)-17A, IL-17F, and IL-22 are abundantly produced in the inflamed gut of patients with Crohn's disease or ulcerative colitis. 10, 11 However, the contribution of each of these cytokines to the pathogenesis of IBDs is not completely understood.
Several studies have investigated the role of IL-17A in various models of colitis. 10 O'Connor et al showed that adoptive transfer of IL-17A-deficient naïve CD4 + T cells to mice with recombination activating gene (RAG)-1 deficiency results in more severe colitis. 12 By contrast, Wedebye Schmidit et al 13 showed that simultaneous neutralization of both IL-17A and IL-17F in vivo suppresses the development of experimental colitis. However, clinically, the blockade of IL-17A alone with secukinumab exacerbated disease activity in patients with Crohn's disease. 14, 15 However, interestingly, vidofludimus which inhibits expression of both IL-17A-and IL-17F-induced favorable responses in steroiddependent IBDs in a phase II clinical study. 16 Thus, simultaneous neutralization of both IL-17A and IL-17F, and not just that of IL-17A alone, maybe a promising target for the treatment of IBDs.
The retinoic acid receptor-related orphan receptor gamma t (RORgt), the master transcription factor of Th17 cell differentiation, controls IL-17A and IL-17F production. 17 Leppkes et al 17 showed that the transfer of RORg-null T cells failed to increase mucosal IL-17A and IL-17F cytokine levels and did not induce colitis. Recently, digoxin, a cardiac glycoside used to treat heart failure, was reported as an inhibitor of RORgt. 18, 19 Interestingly, digoxin treatment attenuated the severity of experimental autoimmune encephalomyelitis in mice 18, 19 and the experimental arthritis in mice. 20 However, the effect of digoxin in experimental colitis has not been reported.
In this study, we administered digoxin to mice with naïve CD4 + T-cell transfer-induced colitis to evaluate its beneficial effect on intestinal inflammation. Here, we show that digoxin attenuates experimental colitis. Furthermore, we demonstrate that digoxin is capable of suppressing of both IL-17A and IL-17F but not tumor necrosis factor alpha (TNF-a) in colonic mucosa in murine T-cell transfer-induced colitis. Therefore, our results suggest that digoxin may be of therapeutic value especially for patients with IBDs refractory to anti-TNF-a therapy.
METHODS

Animals
Eight week-old female C.B-17/severe combined immunodeficiency (SCID) and BALB/c mice were purchased from Japan SLC (Hamamatsu, Japan). Mice were maintained in JIC RAC (CLEA Japan, Tokyo, Japan) under a constant 12-h dark/light cycle and were given standard rodent chow and water ad libitum under specific pathogen-free conditions in an animal facility. 21 Six week-old female IL-10 KO BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, ME). In-house monitoring was performed every 3 months using a Monilisa IVA kit (Wakamoto Pharmaceutical Co., Ltd., Tokyo, Japan) that detects 4 major organisms: Sendai virus, mouse hepatitis virus, mycoplasma, and Tyzzer's organism. No infections were detected in any of the rooms in which mice used in this study were maintained. The study was performed according to the guidelines and regulations for Laboratory Animal Care of Hamamatsu University School of Medicine.
Adoptive Transfer Colitis
Spleen cells were removed from BALB/c mice and suspended into magnetic-activated cell separation (MACS) buffer (Miltenyi Biotec, Bergisch Gladbach, Germany). Erythrocytes were removed by a red blood cell lysis solution (Miltenyi Biotec). CD4 + T cells were isolated by a CD4 + T cell isolation kit II (Miltenyi Biotec), MidiMACS Separator LS (Miltenyi Biotec), and MACS LS column (Miltenyi Biotec). 22 The resulting population was .92% CD4 + T cells. CD4 T cells were labeled with anti-CD45RB FITC antibody (BioLegend, San Diego, CA), anti-CD4 PE antibody (BioLegend), and anti-CD25 APC antibody (BioLegend), and then CD4 + CD25 2 CD45RB high (defined as 20% brightest staining) 23 was sorted by a BD FACSAria cell sorter. C.B-17/SCID mice were injected intraperitoneally with 100 mL of phosphate-buffered saline (PBS) containing 2.0 · 10 5 CD4 + CD25 2 CD45RB high T cells. 22 
Histology
The proximal colon and distal colon were removed from C.B-17/SCID mice, and preserved in PBS containing 10% formalin, and the paraffin embedded. The samples were cut longitudinally and stained with hematoxylin and eosin. A histopathological examination was completed. Briefly, the 4 parameters used included (1) severity of inflammation, range 0 to 3; (2) extent of inflammation, range 0 to 3; (3) amount of mucus, range 0 to 4; and (4) degree of proliferation, range 0 to 3. The maximal score obtainable is 13. 24 
Immunohistochemical Staining
Immunohistochemical staining was performed on paraffinembedded sections of colon tissue from C.B-17/SCID mice. Antigen retrieval was performed by autoclaving the slides in Novocastra Epitope retrieval solution (Leica Biosystems Newcastle, Newcastle upon Tyne, United Kingdom) for 20 minutes at 1208C. The slides were blocked with 10% goat serum (Nichirei Bio Science, Tokyo, Japan) for 10 minutes at room temperature. The sections were incubated with rabbit anti-CD3 primary antibody (1:200 dilution; Nichirei Bio Science) for 30 minutes at room temperature. Detection was performed with peroxidaselabeled anti-rabbit secondary antibody and diaminobenzidine tetrahydrochloride (Nichirei Bio Science). The sections were counterstained with Mayer's hematoxylin (Merck, Darmstadt, Germany), dehydrated and mounted. 13 
RNA Preparation and Real-time Polymerase Chain Reaction (PCR) for Cytokine Expression
Colons were removed from C.B-17/SCID mice, opened longitudinally, and washed in PBS. Then, they were preserved in 1· Hank's balanced salt solution (Life Technologies, Carlsbad, CA) with 5 mM ethylenediaminetetraacetic acid (EDTA) and incubated at 378C for 20 minutes in a shaking water bath. After, the epithelium was removed and immediately homogenized with TRIzol reagent (Life Technologies). Total RNA was extracted according to the previously described method. 25 For reverse transcription, SuperScript VILO cDNA synthesis kit (Life Technologies) was used on GeneAmp PCR system (Applied Biosystems, Foster City, CA). Gene expression quantification for IL-17A, IL-17F, IL-23R, interferon (IFN)-g, TNF-a, IL-10, and RORgt was performed using cDNA specific TaqMan Gene Expression Assays (Applied Biosystems) as the second step in a 2-step PCR. The real-time quantitative PCR reaction was performed after preamplification using 48.48 Dynamic Array IFC (Fluidigm Corporation, South San Francisco, CA). The amplification program was as follows: 958C for 10 minutes, 40 cycles of 958C for 15 seconds, and 608C for 1 minute. Data were analyzed using Fluidigm realtime PCR analysis software 3.0.2 (Fluidigm Corporation).
Cytokine expression was normalized to 18S rRNA expression and represented as a fold change relative to the control SCID mice.
Isolation of Lamina Propria Mononuclear Cells (LPMCs)
Colons were removed from C.B-17/SCID mice, opened longitudinally, and washed in PBS; then they were preserved in 1· Hank's balanced salt solution (Life Technologies) with 5 mM EDTA and incubated at 378C for 20 minutes in a shaking water bath. After the epithelium was removed and cut into small pieces and digested in Roswell Park Memorial Institute 1640 containing with 4% bovine serum albumin, 1 mg/mL collagenase D (Roche Diagnostics, Mannheim, Germany), 0.5 mg/mL Dispase (Life Technologies), and, 40 mg/mL DNase I (Roche Diagnostics) for 60 minutes in a shaking water bath. The digested colons were centrifuged and resuspended in 40% Percoll (GE Healthcare, Little Chalfont, United Kingdom) and then overlaid on 2.5 mL of 80% Percoll. Percoll gradient separation was performed and the LPMC were collected at the interface of Percoll gradient. 26 
Intracellular Cytokine Staining
LPMCs (2 · 10 6 cells/mL) were stimulated with 50 ng/mL of phorbol myristate acetate (Sigma-Aldrich, St. Louis, MO) and 1000 ng/mL of ionomycin (Sigma-Aldrich) for 6 hours at 378C with BD GolgiPlug (Becton Dickinson and Company (BD), Franklin Lakes, NJ). 27 Thereafter, cells were suspended in PBS with EDTA and BSA, incubated with Mouse BD Fc block (BD) for 10 minutes and incubated with an anti-CD4 FITC antibody (BioLegend), and anti-CD3 PerCp/Cy5.5 antibody (BioLegend) for 30 minutes. Thereafter, cells were fixed and permeabilized using a BD Cytofix/Cytoperm kit (BD). Cells were labeled with the anti-IL17A PE/Cy-7 antibody (BioLegend), anti-IFN-g APC antibody (BioLegend), and anti-IL17F PE antibody (BioLegend) for 30 minutes. Cell fluorescence was measured using a Gallios cytometer (Beckman Coulter, Brea, CA) and analyzed using Flow Jo software (Flow Jo, LLC, Ashland, OR).
FOXP3 Staining
LPMCs were suspended in PBS with EDTA and BSA, incubated with Mouse BD Fc block (BD) for 10 minutes and incubated with an anti-CD4 FITC antibody (BioLegend), and anti-CD3 PerCp/Cy5.5 antibody (BioLegend) for 30 minutes. Thereafter, cells were fixed and permeabilized using a BD Transcription Factor Staining Set (BD). Cells were labeled with the anti-mouse FOXP3 Alexa Fluor 647 antibody (eBioscience, Santa Clara, CA) for 50 minutes. Cell fluorescence was measured using a Gallios cytometer (Beckman Coulter) and analyzed using Flow Jo software (Flow Jo, LLC).
Statistical Analysis
Data were expressed as mean 6 SEM. Student's t test or Mann-Whitney U test was used for comparison between more than 2 groups. P , 0.05 was considered statistically significant. Statistical analysis was done using Stat View 5.0 statistical software (SAS Institute, Cary, NC).
RESULTS
In Vivo Experimental Design and Protocol of Digoxin Therapy
The in vivo experimental design and protocol of digoxin therapy are shown in Figure 1A . C.B-17/SCID mice were reconstituted with CD4 + CD25 2 CD45RB high (naïve) T cells (2 · 10 5 cells/body). To avoid the contamination of CD45RB low/intermediate cells, which retain some immunosuppressive property, we sorted the 20% brightest CD45RB high CD4 T cells using flow cytometric analysis. As a treatment for experimental colitis, we intraperitoneally injected 5 mg/kg digoxin, 0.5 mg/kg digoxin, or a vehicle (3% carboxymethyl cellulose/PBS) into SCID mice thrice weekly from day 3 after T-cell transfer.
Digoxin Therapy Affects Body Weights of Mice with Experimental Colitis
We first assessed whether digoxin treatment could affect body weights of mice without colitis. In the group of SCID mice without naïve T-cell transfer, body weights of both vehicle-treated mice and digoxin-treated mice increased gradually during the observation period (Fig. 1B) . Conversely, in the group of SCID mice reconstituted with naïve T cells, the body weights of the vehicle-treated mice decreased significantly from week 5, whereas body weights of the digoxin-treated mice did not decrease from week 5 and were significantly higher than those of vehicle-treated mice from week 6 to 8 (Fig. 1B) . Because 5 mg/kg of digoxin is a high dose for humans, we tested a lower dose (0.5 mg/kg) digoxin in mice with colitis. The body weight of 0.5-mg/kg digoxin-treated mice tended to be higher than vehicle-treated mice at week 5; however, it did not reach statistical significance. The body weight in 5-mg/kg digoxin-treated mice was significantly higher than vehicle-treated mice at week 5, and there was no significant difference between the body weight of 5-mg/kg digoxin-treated mice and 0.5-mg/kg digoxin-treated mice at week 5 (Fig. 1C) .
Digoxin Therapy Improves Gross and Histologic Images of Experimental Colitis
Because the peak of colitis was observed at 6 weeks after naïve T-cell transfer, we killed the mice at that time for histological assessment. As previously described, 28 the presence and progression of colitis were grossly determined by measuring the diameter of the inflamed colon; the diameter of colons increased with the severity and progression of the experimental colitis. Digoxin treatment effectively suppressed the increase in the diameter of colon of the SCID mice reconstituted with naïve T cells (Fig. 2A) . The length of the colon in digoxin-treated mice did not differ significantly from that of vehicle-treated mice (data not shown). This result was further confirmed by the histologic examination of colon. In vehicle-treated colitis mice, distortion of crypts, loss of goblet cells, and inflammatory cell infiltration were observed in both the proximal colon and distal colon (Fig. 2B, D) . These inflammatory cells were mainly CD3 + T cells (Fig. 2B, D) . Of note, treatment with digoxin reduced CD3 + T-cell infiltration and was accompanied by an improvement in the histologic images (Fig. 2B, D) . The histological colitis scores in both the proximal and distal colon of the digoxin-treated mice were lower than those of vehicle-treated mice with colitis (Fig. 2C, E) . 
Digoxin Predominantly Suppresses Th17 Cells Rather than Th1 Cells in Inflamed Colonic Mucosa
We next investigated whether digoxin therapy could influence the balance of Th subsets in the inflamed colonic mucosa. LPMCs were isolated from the large intestine of mice with colitis, and flow cytometric analysis for cytoplasmic staining of IL-17A, IL-17F, and IFN-g was performed. The proportion of IL-17A + CD4 + T cells decreased in digoxintreated mice compared with that in vehicle-treated mice (Fig.  3A, B) . By contrast, there was no significant difference in the proportion of IFN-g + CD4 + T cells between digoxin-treated mice and vehicle-treated mice (Fig. 3A, B) . IL-17F + CD4 + T cells could not be detected in the LPMC of both digoxintreated and vehicle-treated mice with colitis. These results indicate that digoxin therapy predominantly suppresses Th17 FIGURE 2. Ability of digoxin to attenuate experimental colitis. A, The diameter of the distal colon was measured at 6 weeks after the transfer of naïve T cells. Each bar represents the mean 6 SEM of 6 to 7 mice in each group. *P , 0.05 by a Student's t test. B-E, Histological findings and immunohistological analysis for CD3 of proximal colon (B) and distal colon (D) from mice with experimental colitis. Histological score of proximal colon (C) and distal colon (E) for mice with experimental colitis. Each circle represents an individual mouse. The histologic scores of both the proximal and distal colon in mice treated with digoxin were significantly lower than those of untreated mice. *P , 0.05 by Mann-Whitney U test.
cells rather than Th1 cells in colonic mucosa of mice with colitis.
Digoxin Upregulates FOXP3 + CD4 + T Cells in the Colonic Mucosa
Previous studies have shown that digoxin upregulates FOXP3 in the murine model of arthritis. 20 Therefore, we investigated the expression of FOXP3 in CD4 + T cells from colonic lamina propria of digoxin-treated or vehicle-treated mice. We showed that the FOXP3 + CD4 + T-cell population in the colonic lamina propria was significantly higher in digoxin-treated mice than in the vehicle-treated mice (Fig. 4) .
Digoxin Predominantly Suppresses Th17 and Th1 Cytokines but Not TNF-a in Inflamed Colonic Tissue
We next evaluated whether the cytokine profile was altered by digoxin therapy in the colonic mucosa of mice with colitis. Colonic tissues were harvested from vehicle-treated mice with colitis and digoxin-treated mice with colitis, and then the expression level of mRNA for cytokines was investigated by realtime PCR (Fig. 4) . As expected, the expression level of mRNA for IL-17A was significantly downregulated in digoxin-treated mice compared with vehicle-treated mice. Furthermore, the expression level of mRNA for IL-17F tends to be downregulated in digoxintreated mice compared with that in vehicle-treated mice. The mRNAs for IFN-g and IL-23R were significantly downregulated in digoxin-treated mice compared with those in vehicle-treated mice. Interestingly, the mRNA for IL-10, an anti-inflammatory cytokine for colitis, was significantly upregulated in digoxintreated mice compared with that in vehicle-treated mice. There was no significant difference in expression level of mRNA for RORg between vehicle-treated mice and digoxin-treated mice (data not shown). Unexpectedly, the expression level of mRNA for TNF-a was not downregulated in digoxin-treated mice compared with that in vehicle-treated mice (Fig. 5) . These results clearly showed that digoxin therapy predominantly suppresses expression of mRNAs for Th17 and Th1 cytokines but not TNF-a in inflamed colonic tissue.
Digoxin Ameliorates the Adoptive Transfer Colitis Reconstituted with Naïve CD4 + T Cells of IL-10 KO Mice
Although we showed that mRNA for IL-10 was significantly upregulated in the colonic tissue of digoxin-treated mice, it was not clear whether the ameliorating effect of digoxin on colitis was mediated by the production of IL-10 alone. Therefore, we reconstituted C.B-17/SCID mice with naïve CD4 + T cells from IL-10 KO BALB/c mice and treated these mice with vehicle or 5 mg/kg/body digoxin. The body weight loss of digoxin-treated mice was significantly lesser than those in vehicle-treated mice at 3 weeks after transfer of the T cells (Fig. 6A) . This result indicated that digoxin could ameliorate the wasting disease in colitis mice reconstituted with IL-10 2 CD4 + T cells. In addition, the histological score for colitis in digoxin-treated mice reconstituted with IL-10 2 CD4 + T cells tended to be lower than that for in vehicle-treated mice reconstituted with IL-10 2 CD4 + T cells 3 weeks after transfer (Fig. 6B, C) ; however, the difference did not reach statistical significance. These results indicated that digoxin ameliorated colitis partially but not fully by an IL-10 dependent pathway.
DISCUSSION
From the findings described in this report, we drew the following conclusions concerning the effect of digoxin on CD4 + CD45RB high T-cell transfer-induced colitis in mice: (1) administration of digoxin significantly attenuates both wasting disease and colonic inflammation, (2) treatment with digoxin markedly reduced CD3 + T-cell infiltration in the lamina propria, (3) treatment with digoxin predominantly suppresses the proportion of Th17 cells rather than Th1 cells in the lamina propria, (4) treatment with digoxin increases the proportion of FOXP3 + CD4 + T cells in the lamina propria, and (5) treatment with digoxin inhibits the mRNA expression of Th17 and Th1 cytokines but not TNF-a in the colonic mucosa.
To investigate whether digoxin has a therapeutic effect on IBD, we administered digoxin to SCID mice with colitis induced by the transfer of naïve CD4 + T cells. In this experimental colitis model, chronic colitis is caused by both Th1 and Th17 responses, which mimics Crohn's disease. 29 The role of Th17 cells in IBD is still controversial. The inhibition of IL-17A alone, which is a representative cytokine for Th17 responses, was ineffective in both patients with Crohn's disease 15 and mice with experimental colitis. 12 However, the simultaneous inhibition of both IL-17A and IL-17F clearly improved IBD in both mice 13 and human. 16 In addition, the inhibition of RORg, known as the master transcription factor guiding Th17 differentiation, ameliorated experimental colitis in mice. 17 Therefore, we expected that digoxin, recently known as a specific inhibitor for RORg, might be a good therapeutic candidate.
In this study, we revealed that treatment with digoxin significantly reduces colitis-induced body weight loss and improves the histologic scores. Along with the histologic improvement, CD3 + T-cell infiltration decreased in the colonic mucosa of mice. Treatment with digoxin predominantly suppressed IL-17A + CD4 + T cells rather than IFN-g + CD4 + T cells in colonic lamina propria. This observation is consistent with a previous study, which showed that RORg-deficient T cells display normal Th1 differentiation but profound defect in Th17 differentiation. 30 In our study, IL-17F + CD4 + T cells could not be detected in the LPMC of both digoxin-treated mice and vehicletreated mice with colitis, probably because the size of the cell population was too small to be detected. To investigate the effect of digoxin on cytokine productions in vivo, we performed quantitative PCR assays using RNA extracted from the colonic mucosa of mice with colitis. Our findings showed that expression of mRNA for IL-17A was significantly downregulated in digoxin-treated mice compared with that in vehicle-treated mice. In addition, expression of mRNA for IL-17F was slightly downregulated in digoxintreated mice compared with that in vehicle-treated mice. Although there was no significant difference in the proportion of IFNg + CD4 + T cells in the colonic lamina propria lymphocyte between digoxin-treated mice and vehicle-treated mice, the expression of mRNA for IFN-g in colonic mucosa was significantly downregulated in digoxin-treated mice compared with that in vehicletreated mice. The reason for this may be that the absolute number of inflammatory cells that produce IFN-g decreased in the colonic mucosa of digoxin-treated mice compared with that of vehicletreated mice or the amounts of IFN-g produced by individual CD4 + T cells in digoxin-treated mice were lower than those in vehicle-treated mice. Unexpectedly, expression of mRNA for IL-10, an anti-inflammatory cytokine, was significantly upregulated in the colonic mucosa of digoxin-treated mice compared with that in vehicle-treated mice. To clarify whether IL-10 was involved in amelioration of colitis with digoxin treatment, we used the adoptive transfer colitis model mice reconstituted with naïve CD4 + T cells from IL-10 KO mice. Interestingly, digoxin could ameliorate the wasting disease in these mice, but did not significantly affect their histological score. Therefore, we suggest that digoxinmediated amelioration of colitis can be attributed only partly to an IL-10 dependent pathway. Gagliani et al 31 demonstrated that under homeostatic conditions, intestinal Th17 cells can lose IL-17 expression and a fraction of these "exTh17" cells acquire regulatory features resembling CD4 + FOXP3 -type 1 regulatory T cells (Tr-1 cells), which produce IL-10. Moreover, a previous study showed that digoxin upregulates FOXP3 in the mouse model of arthritis. 20 In our study, we also showed that FOXP3 + CD4 + T-cell population was significantly increased in colonic lamina propria of digoxin-treated mice than that of vehicle-treated mice. However, because there was no data showing that digoxin could drive Th17 cells toward regulatory phenotypes, including IL-10-producing CD4 + T cells, further research is required to elucidate this point. Furthermore, we did not assess other subsets of IL-10-producing cells, such as B cells and macrophages. Yanaba et al 32 showed that CD1d hi CD5 + regulatory B cells attenuated dextran sulfate sodium-induced colitis of mice through IL-10. Krause et al 33 showed IL-10-producing intestinal macrophages attenuated colitis in a Citrobacter rodentium-infected mouse model of colitis. However, assessing the role of IL-10-producing B cells in our T-cell transfer-induced colitis model is challenging because of the scarcity of B cells in this model. In addition, further studies would be required to elucidate the role of IL-10-producing intestinal macrophages in our model.
Another interesting observation of our study was that treatment with digoxin improved colitis without downregulation of expression of mRNA for TNF-a in the colonic mucosa. Of note, Leal et al 34 reported that patients with Crohn's disease who failed to respond to anti-TNF-a therapy maintain an increased expression of IL-17A and IL-1b, which is necessary for the differentiation of Th17 cells. 35 Therefore, using digoxin for anti-TNF-a nonresponders to suppress Th17 cells would seem to be a rational strategy. In our study, the mRNA expression of RORg, the master transcription factor guiding Th17 differentiation, was not downregulated in the colonic mucosa of mice treated with digoxin (data not shown). A previous study showed that, during the in vitro differentiation of Th17 cells differentiation from naïve CD4 T cells, digoxin treatment downregulated IL-17A mRNA expression, but not RORg mRNA expression. 19 In addition, Huh et al 18 showed that, in the Drosophila S2 cell luciferase reporter system, digoxin inhibited RORg activity but not RORg protein expression. These previous data clearly demonstrate that digoxin inhibits RORg activity without altering RORg expression and subsequently downregulates IL-17A mRNA expression.
Digoxin, an inhibitor of Na + /K + -ATPase, is widely used for treatment of congestive heart failure and cardiac arrhythmia. 36 However, the most concerning issue is that digoxin is toxic at concentrations below those required for inhibition of RORg activation. 37 In our study, severe adverse events were not observed in digoxin-treated mice. This reason for this would be that the catalytic a1 subunit of murine Na + /K + -ATPase binds to digoxin poorly. 38 However, to consider using digoxin for the treatment of Crohn's disease, this critical problem of toxicity in humans must be solved. Therefore, using nontoxic digoxin analogs such as 20,22-dihydrodigoxin-21,23-diol or digoxin-21-salicylidene which can inhibit the induction of IL-17 in human CD4 + T cells may be more suitable for clinical trials of Crohn's disease. 18 In conclusion, our findings showed that digoxin can significantly attenuate the colonic inflammation induced by naïve T-cell transfer into SCID mice. We have also shown that treatment with digoxin suppresses expression of mRNAs for Th17 cytokines but not mRNA for TNF-a in the colonic mucosa of SCID mice with transferred naïve T cells. Our finding suggest that digoxin or nontoxic digoxin analogs may be of therapeutic value for the treatment of Crohn's disease in cases where patients are unresponsive to anti-TNF-a therapy.
